Clinical interpretation:

?Evidence is not yet sufficient to conclude that resmetirom prevents cirrhosis, hepatic decompensation, transplantation, liver cancer, cardiovascular events, or mortality.Not a substitute for metabolic management: It is indicated with diet and exercise, while diabetes, obesity, hypertension, and dyslipidemia still require optimized management.Lipid benefit: The LDL-C reduction may be particularly advantageous because many patients with MASH have substantial cardiometabolic risk.No established hard-outcome benefit yet: Current approvals are based on surrogate histologic endpoints.MASH resolution: Absolute benefit was approximately 16-20 percentage points beyond placebo.Fibrosis regression: Absolute benefit was approximately 10-12 percentage points beyond placebo.????